AIM ImmunoTech AIM

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.00 (+1.71%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of AIM ImmunoTech (AIM)
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $0.133

  • Market Cap

    $9.14 Million

  • Price-Earnings Ratio

    -2.22

  • Total Outstanding Shares

    68.75 Million Shares

  • Total Employees

    28

  • Dividend

    No dividend

  • IPO Date

    November 2, 1995

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Primary Exchange

    American Stock Exchange

  • Type

    Common Stock

  • Headquarters

    2117 sw highway 484, Ocala, FL, 32801

  • Homepage

    https://www.aimimmuno.com

Historical Stock Splits

If you bought 528 shares of AIM before August 29, 2016, you'd have 1 share today.
Execution DateSplit Amount
June 11, 20191-for-44 (Reverse Split)
August 29, 20161-for-12 (Reverse Split)

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$137,000
Net Cash Flow, Continuing$-2.64 Million
Net Cash Flow From Investing Activities, Continuing$334,000
Net Cash Flow From Operating Activities, Continuing$-3.11 Million
Net Cash Flow From Financing Activities$137,000
Net Cash Flow From Investing Activities$334,000

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Diluted Average Shares$57.68 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Costs And Expenses$4.52 Million
Income/Loss From Continuing Operations Before Tax$-4.49 Million
Net Income/Loss Available To Common Stockholders, Basic$-3.70 Million
Revenues$35,000

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Comprehensive Income/Loss$-3.70 Million
Other Comprehensive Income/Loss$-3.70 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-3.70 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Liabilities And Equity$13.59 Million
Wages$1,000
Current Assets$7.57 Million
Equity Attributable To Parent$2.91 Million
Noncurrent Assets$6.02 Million
Other Non-current Assets$5.90 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AIM from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.